🚀 VC round data is live in beta, check it out!
Lavipharm Valuation Multiples
Discover revenue and EBITDA valuation multiples for Lavipharm and similar public comparables like Antibiotice, Alector, Dishman Carbogen Amics, C4 Therapeutics and more.
Lavipharm Overview
About Lavipharm
Lavipharm SA develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. The company's product portfolio includes safe and effective therapeutic solutions that meet consumers' needs for health and well-being. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, General Medicine, Self-Treatment, and Dermocosmetic care. Its operating segments include Medicines, Parapharmaceuticals, and Services.
Founded
1911
HQ
Employees
299
Website
Financials (FY)
EV
$315M
Lavipharm Financials
Lavipharm reported last fiscal year revenue of $62M and EBITDA of $12M.
In the same fiscal year, Lavipharm generated $30M in gross profit, $12M in EBITDA, and $11M in net income.
Lavipharm P&L
In the most recent fiscal year, Lavipharm reported revenue of $62M and EBITDA of $12M.
Lavipharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $62M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $30M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 47% | XXX | XXX | XXX |
| EBITDA | — | XXX | $12M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 19% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 10% | XXX | XXX | XXX |
| Net Profit | — | XXX | $11M | XXX | XXX | XXX |
| Net Margin | — | XXX | 17% | XXX | XXX | XXX |
| Net Debt | — | — | $20M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Lavipharm Stock Performance
Lavipharm has current market cap of $283M, and enterprise value of $315M.
Market Cap Evolution
Lavipharm's stock price is $1.67.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $315M | $283M | 1.8% | XXX | XXX | XXX | $0.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLavipharm Valuation Multiples
Lavipharm trades at 5.1x EV/Revenue multiple, and 26.2x EV/EBITDA.
Lavipharm Financial Valuation Multiples
As of April 18, 2026, Lavipharm has market cap of $283M and EV of $315M.
Equity research analysts estimate Lavipharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lavipharm has a P/E ratio of 26.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $283M | XXX | $283M | XXX | XXX | XXX |
| EV (current) | $315M | XXX | $315M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 5.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 26.2x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 48.9x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 10.7x | XXX | XXX | XXX |
| P/E | — | XXX | 26.7x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (53.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Lavipharm Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Lavipharm Margins & Growth Rates
Lavipharm's revenue in the last fiscal year grew by 4%.
Lavipharm's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Lavipharm Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 3% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 13% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 37% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Lavipharm Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Health & Beauty comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Antibiotice | XXX | XXX | XXX | XXX | XXX | XXX |
| Alector | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| C4 Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Prelude Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lavipharm M&A Activity
Lavipharm acquired XXX companies to date.
Last acquisition by Lavipharm was on XXXXXXXX, XXXXX. Lavipharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Lavipharm
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLavipharm Investment Activity
Lavipharm invested in XXX companies to date.
Lavipharm made its latest investment on XXXXXXXX, XXXXX. Lavipharm invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Lavipharm
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Lavipharm
| When was Lavipharm founded? | Lavipharm was founded in 1911. |
| Where is Lavipharm headquartered? | Lavipharm is headquartered in Greece. |
| How many employees does Lavipharm have? | As of today, Lavipharm has over 299 employees. |
| Is Lavipharm publicly listed? | Yes, Lavipharm is a public company listed on Athens Stock Exchange. |
| What is the stock symbol of Lavipharm? | Lavipharm trades under LAVI ticker. |
| When did Lavipharm go public? | Lavipharm went public in 1995. |
| Who are competitors of Lavipharm? | Lavipharm main competitors are Antibiotice, Alector, Dishman Carbogen Amics, C4 Therapeutics. |
| What is the current market cap of Lavipharm? | Lavipharm's current market cap is $283M. |
| What is the current revenue of Lavipharm? | Lavipharm's last fiscal year revenue is $62M. |
| What is the current EV/Revenue multiple of Lavipharm? | Current revenue multiple of Lavipharm is 5.1x. |
| Is Lavipharm profitable? | No, Lavipharm is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.